← Back to patent-cliff list
CAS 1782958-99-9
(3aS,9aS,10S,12S,13aR,13bS)-12-Hydroxy-6,9a,14,14-tetramethyl-13-methylene-10-[(triethylsilyl)oxy]-9,9a,10,11,12,13,13a,13b-octahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-2,8(5H)-dione
Codes：(XVIII)101438-13-b
Application context (from source-drug indications)
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(2alpha,5beta,7beta,10beta)-1,2,7,10-Tetrahydroxytaxa-4(20),11-dien-5-yl acetate→1-[(1H-Imidazol-1-yl)carbonyl]1H-imidazole→(3aS,9aS,10S,12R,13S,13aR,13bS)-12,13-Dihydroxy-13-(hydroxymethyl)-6,9a,14,14-tetramethyl-10-[(triethylsilyl)oxy]-9,9a,10,11,12,13,13a,13b-octahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-2,8(5H)-dione→(3aS,8S,9aS,10S,12R,13aR,13bS)-8,10-Dihydroxy-6,9a,14,14-tetramethyl-13-methylene-2-oxo-5,8,9,9a,10,11,12,13,13a,13b-decahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-12-yl acetate→(3aS,8S,9aS,10S,12R,13aR,13bS)-8-Hydroxy-6,9a,14,14-tetramethyl-13-methylene-2-oxo-10-[(triethylsilyl)oxy]-5,8,9,9a,10,11,12,13,13a,13b-decahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-12-yl acetate→(3aS,9aS,10S,12R,13aR,13bS)-6,9a,14,14-Tetramethyl-13-methylene-2,8-dioxo-10-[(triethylsilyl)oxy]-5,8,9,9a,10,11,12,13,13a,13b-decahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-12-yl acetate→(3aS,9aS,10S,12S,13aR,13bS)-12-Hydroxy-6,9a,14,14-tetramethyl-13-methylene-10-[(triethylsilyl)oxy]-9,9a,10,11,12,13,13a,13b-octahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-2,8(5H)-dione→[(3aS,9aS,10S,12R,13S,13aR,13bS)-12,13-Dihydroxy-6,9a,14,14-tetramethyl-2,8-dioxo-10-[(triethylsilyl)oxy]-5,8,9,9a,10,11,12,13,13a,13b-decahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-13-yl]methyl acetate→[(3aS,9aS,10S,12R,13S,13aR,13bS)-13-Hydroxy-6,9a,14,14-tetramethyl-12-[(methylsulfonyl)oxy]-2,8-dioxo-10-[(triethylsilyl)oxy]-5,8,9,9a,10,11,12,13,13a,13b-decahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-13-yl]methyl acetate→(3aS,9aS,10S,12S,13S,13aR,13bS)-13-Hydroxy-13-(hydroxymethyl)-6,9a,14,14-tetramethyl-2,8-dioxo-10-[(triethylsilyl)oxy]-5,8,9,9a,10,11,12,13,13a,13b-decahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-12-yl methanesulfonate→(3aS,9aS,10S,11aR,13aS,13bR,13cS)-13a-Hydroxy-6,9a,14,14-tetramethyl-10-[(triethylsilyl)oxy]-4,5,9a,10,11,11a,13,13a,13b,13c-decahydro-3a,7-methano[1,3]dioxolo[9,10]cyclodeca[1,2-d][1]benzoxete-2,8(9H)-dione
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.